- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.04. | Moss Genomics Inc: Moss launches Perennial, closes on 130 ethereum | 1 | Stockwatch | ||
| 28.04. | Moss Genomics Inc.: Moss Genomics Launches "Perennial" Genomics Platform, Closes on 130 ETH | 283 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 28, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is pleased to announce the public launch of its genomics... ► Artikel lesen | |
| 11.04. | Moss Genomics Inc: Moss Genomics lists on OTCQB Venture Market | 3 | Stockwatch | ||
| 11.04. | Moss Genomics Inc.: Moss Genomics Announces Listing on the OTC Markets | 350 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 11, 2025) - Moss Genomics Inc. (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) (the "Company" or "Moss") is pleased to announce that its common shares are... ► Artikel lesen | |
| 26.02. | Moss Genomics Inc: Moss Genomics appoints director, fractional CFO | 2 | Stockwatch | ||
| MOSS GENOMICS Aktie jetzt für 0€ handeln | |||||
| 26.02. | Moss Genomics Inc. Announces Leadership Changes | 150 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 26, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) ("Moss" or the "Company") is pleased to announce the appointment of Joseph De Pinto to... ► Artikel lesen | |
| 25.02. | Moss Genomics Inc: Moss Genomics doubles down on blockchain, ethereum | 1 | Stockwatch | ||
| 25.02. | Moss Genomics Inc.: Moss Genomics Announces Genomics Business Update, Integrating Blockchain for Genomic Security and Transparency | 152 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 25, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss Genomics") is pleased to provide an update on its business strategy... ► Artikel lesen | |
| 04.02. | Moss Genomics Inc.: Moss Genomics Announces Private Placement and Agreement to Acquire Ethereum | 537 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 3, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to announce a non-brokered private placement of up... ► Artikel lesen | |
| 01.02. | Moss Genomics Inc: Moss Genomics closes $250,000 private placement | 1 | Stockwatch | ||
| 01.02. | Moss Genomics Inc.: Moss Genomics Announces Closing of Private Placement, Acquisition of 160 Ethereum Cryptocurrency (ETH) and Welcomes Hunter Jordan to Its Board of Directors | 1.069 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 31, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to announce that is has closed its previously announced... ► Artikel lesen | |
| 24.01. | Moss Genomics Inc: Moss to change business focus to ethereum | 2 | Stockwatch | ||
| 24.01. | Moss Genomics Inc.: Moss Genomics Provides Corporate Update and Announces Shift in Business Strategy | 847 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 24, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to provide an update on the Company's operations and... ► Artikel lesen | |
| 14.01. | Moss Genomics Inc. Announces Successful German Listing on the Frankfurt Stock Exchange (FSE) | 255 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss Genomics") is pleased to announce that it has successfully listed... ► Artikel lesen | |
| 14.01. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 14.01.2025 | 331 | Xetra Newsboard | The following instruments on XETRA do have their first trading 14.01.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2025
Aktien
1 CA61965T1012 Moss Genomics Inc.
2... ► Artikel lesen | |
| 24.12.24 | Moss Genomics Inc: Moss appoints Liu as CEO, director; to buy 160 ETH | 5 | Stockwatch | ||
| 24.12.24 | Moss Genomics Inc.: Canadian Company Moss Genomics Announces Agreement to Acquire Ethereum, Appoints Jack Liu as CEO and Director, Private Placement and Option Grant | 768 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 24, 2024) - Moss Genomics Inc. (CSE: MOSS) (the "Company" or "Moss") today announced the appointment of Jack Liu as CEO and a Director of the... ► Artikel lesen | |
| 18.07.24 | Moss Genomics Inc. Welcomes Martin Bajic to Its Board | 553 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - July 18, 2024) - Moss Genomics Inc. (CSE: MOSS) (the "Company" or "Moss") is pleased to announce that it has appointed Martin Bajic to its Board of Directors.... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
| TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
| BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
| VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
| JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
| EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
| 89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |
Das Unternehmen MOSS GENOMICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,076 Euro und damit -27,62 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOSS GENOMICS INC finden Sie auf Wallstreet Online.